SS-31 (Elamipretide): The Cardiolipin Mitochondrial Peptide
Elamipretide — research designation SS-31 — is a small mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane via cardiolipin binding. It is one of the few mitochondria-targeted peptides to reach late-stage human trials.
elamipretide is a tetrapeptide (D-Arg-2'6'-dimethyltyrosine-Lys-Phe-NH2).
approximate concentration enrichment in the inner mitochondrial membrane via cardiolipin binding.
elamipretide has reached phase 3 trials in specific indications (Barth syndrome cardiomyopathy, dry AMD).
phase 3 results have been mixed across indications; ongoing development continues.
SS-31 / elamipretide is a tetrapeptide engineered to selectively concentrate in the inner mitochondrial membrane, where it binds cardiolipin — a phospholipid central to electron transport chain function. The pharmacology is well-characterised: mitochondrial targeting, ATP production support, reactive oxygen species reduction in dysfunctional mitochondria. Phase 3 read-outs have been mixed: positive signals in specific genetic mitochondrial cardiomyopathies, less clear results in age-related macular degeneration. The development story is unusually instructive about how mitochondrial-targeted therapeutics translate to clinical endpoints.
A mitochondria-targeted peptide with mechanism-first design and a real phase 3 programme. The translation to clinical endpoints has been more nuanced than the mechanism alone predicted.
What it is
Elamipretide is a synthetic tetrapeptide (D-Arg-2'6'-Dmt-Lys-Phe-NH2) designed by Hazel Szeto's lab. Its defining feature is selective accumulation in the inner mitochondrial membrane via electrostatic and structural interaction with cardiolipin.
Cardiolipin is a phospholipid almost exclusive to the inner mitochondrial membrane, where it stabilises electron transport chain complexes. Cardiolipin oxidation and depletion are hallmarks of mitochondrial dysfunction in ageing and disease.
By concentrating in this membrane, elamipretide is hypothesised to stabilise cardiolipin, support ETC function, reduce mitochondrial ROS production and improve ATP output in dysfunctional cells.
Pharmacology
| Layer | What the research describes |
|---|---|
| Cardiolipin binding | Direct binding to cardiolipin in the inner mitochondrial membrane via electrostatic and structural interaction. |
| Mitochondrial concentration | Achieves 1000–5000× concentration enrichment in mitochondrial membrane vs cytosol. |
| ETC stabilisation | Stabilises electron transport chain complex assembly in models of dysfunction. |
| ROS reduction | Reduces reactive oxygen species generation in dysfunctional (not healthy) mitochondria. |
| ATP support | Improves ATP synthesis efficiency in cells with mitochondrial dysfunction. |
The pharmacology is mechanism-first and elegant. The clinical question has been whether mechanism-level fixes translate to patient-level endpoints in the chosen indications.
Phase 3 development across indications
Barth syndrome cardiomyopathy
Genetic mitochondrial cardiomyopathy caused by cardiolipin remodelling defects — mechanistically the cleanest target. Phase 3 data have shown positive signals in this rare population.
Dry age-related macular degeneration
Mitochondrial dysfunction in retinal pigment epithelium hypothesised; phase 3 ReCLAIM-2 produced mixed results.
Heart failure with preserved ejection fraction
Earlier-phase studies; mixed signals; mechanistic rationale exists but clinical translation incomplete.
Mitochondrial myopathies
Investigational use across several rare mitochondrial diseases; results mixed by indication.
The instructive feature of the elamipretide programme is that mechanism-first peptides face the same clinical-translation problem as any other class. Cardiolipin binding is real; ATP support is real; but downstream patient-relevant endpoints depend on whether the underlying disease is dominantly cardiolipin-driven.
Barth syndrome is mechanistically the cleanest fit — the genetic defect is in cardiolipin remodelling itself. Broader indications where mitochondrial dysfunction is one of many drivers show smaller and more variable effects.
What we know, what's still open
- Mitochondrial targeting: Well-characterised pharmacology.
- Mechanism (cardiolipin): Strong biochemical evidence.
- Barth syndrome efficacy: Positive phase 3 signal in rare-disease population.
- Dry AMD efficacy: Mixed; not yet a definitive approval pathway.
- General 'mitochondrial enhancement': Not supported by current clinical evidence in healthy or general populations.
Frequently asked
Is it approved?
Approval discussions are indication-specific. As of 2025, regulatory status varies and is in flux for specific rare indications.
Does it help healthy people's mitochondria?
Mechanism suggests effect on dysfunctional mitochondria primarily; healthy-population clinical evidence is absent. The pharmacology is described as 'restoring' rather than 'enhancing'.
How does it relate to MOTS-c?
Different mechanism entirely. MOTS-c is a mitochondrial-derived signal peptide; elamipretide is a structural-membrane-binding mitochondrial-targeting peptide.
Is it safe?
Safety profile has been favourable across trials; specific adverse-event data in approved-population context still maturing.
Where to read further
- • Szeto HH. First-in-class cardiolipin-protective compounds. Br J Pharmacol 2014.
- • Reid Thompson W et al. Elamipretide in Barth syndrome — phase 2/3 trials.
- • ReCLAIM-2 dry AMD results — see publications and FDA briefing documents.